David Turkaly
Stock Analyst at JMP Securities
(2.24)
# 1,235
Out of 4,650 analysts
134
Total ratings
41.41%
Success rate
-3.95%
Average return
Main Sectors:
Stocks Rated by David Turkaly
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
ENOV Enovis | Initiates: Market Outperform | $62 | $40.51 | +53.05% | 1 | Oct 3, 2024 | |
APYX Apyx Medical | Reiterates: Market Perform | n/a | $1.25 | - | 5 | Sep 16, 2024 | |
KIDS OrthoPediatrics | Reiterates: Market Outperform | $50 | $26.59 | +88.04% | 9 | Sep 13, 2024 | |
STIM Neuronetics | Maintains: Market Outperform | $7 → $3 | $1.01 | +197.03% | 7 | Aug 14, 2024 | |
HAE Haemonetics | Reiterates: Market Outperform | $125 | $73.10 | +71.00% | 10 | Aug 13, 2024 | |
TELA TELA Bio | Maintains: Market Outperform | $15 → $12 | $2.87 | +318.12% | 5 | Aug 13, 2024 | |
AXGN Axogen | Maintains: Market Outperform | $17 → $20 | $13.96 | +43.27% | 6 | Aug 9, 2024 | |
STE STERIS | Reiterates: Market Outperform | $265 | $223.87 | +18.37% | 15 | Aug 7, 2024 | |
NVRO Nevro | Downgrades: Market Perform | n/a | $5.25 | - | 13 | Aug 7, 2024 | |
LNTH Lantheus Holdings | Maintains: Market Outperform | $130 → $125 | $110.09 | +13.54% | 6 | Aug 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $40 → $35 | $19.50 | +79.49% | 13 | Jul 30, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $20 | $5.19 | +285.36% | 4 | May 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $13.11 | +144.09% | 6 | May 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $16.36 | - | 1 | Apr 22, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $285 | $236.44 | +20.54% | 14 | Feb 23, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $160 → $140 | $103.88 | +34.77% | 13 | Nov 13, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $74.29 | - | 1 | May 24, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $4 | $1.90 | +110.53% | 4 | Apr 13, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $6.58 | -24.01% | 1 | Oct 6, 2017 |
Enovis
Oct 3, 2024
Initiates: Market Outperform
Price Target: $62
Current: $40.51
Upside: +53.05%
Apyx Medical
Sep 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $1.25
Upside: -
OrthoPediatrics
Sep 13, 2024
Reiterates: Market Outperform
Price Target: $50
Current: $26.59
Upside: +88.04%
Neuronetics
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $1.01
Upside: +197.03%
Haemonetics
Aug 13, 2024
Reiterates: Market Outperform
Price Target: $125
Current: $73.10
Upside: +71.00%
TELA Bio
Aug 13, 2024
Maintains: Market Outperform
Price Target: $15 → $12
Current: $2.87
Upside: +318.12%
Axogen
Aug 9, 2024
Maintains: Market Outperform
Price Target: $17 → $20
Current: $13.96
Upside: +43.27%
STERIS
Aug 7, 2024
Reiterates: Market Outperform
Price Target: $265
Current: $223.87
Upside: +18.37%
Nevro
Aug 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $5.25
Upside: -
Lantheus Holdings
Aug 1, 2024
Maintains: Market Outperform
Price Target: $130 → $125
Current: $110.09
Upside: +13.54%
Jul 30, 2024
Maintains: Market Outperform
Price Target: $40 → $35
Current: $19.50
Upside: +79.49%
May 9, 2024
Maintains: Market Outperform
Price Target: $23 → $20
Current: $5.19
Upside: +285.36%
May 7, 2024
Reiterates: Market Outperform
Price Target: $32
Current: $13.11
Upside: +144.09%
Apr 22, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $16.36
Upside: -
Feb 23, 2024
Reiterates: Market Outperform
Price Target: $285
Current: $236.44
Upside: +20.54%
Nov 13, 2023
Maintains: Market Outperform
Price Target: $160 → $140
Current: $103.88
Upside: +34.77%
May 24, 2023
Reiterates: Market Perform
Price Target: n/a
Current: $74.29
Upside: -
Apr 13, 2023
Maintains: Outperform
Price Target: $7 → $4
Current: $1.90
Upside: +110.53%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $6.58
Upside: -24.01%